Complete Response Letters: Industry Prefers Communication Before Rather Than Docs After
Executive Summary
Rep. Dunn’s idea would be a return to prior agency practice; the documents are currently considered exempt from disclosure.
You may also be interested in...
Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill
Legislation in development also could create an option for tentative approval of interchangeable biosimilars.
Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill
Legislation in development also could create an option for tentative approval of interchangeable biosimilars.
US FDA Orphan Exclusivity Would Revert To Pre-Catalyst Status Under Senate Legislation
Federal court decision said the FDA cannot grant orphan exclusivity for subpopulations of a disease, which agency officials fear could damage pediatric rare disease drug development.